Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Purpose: Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone–mediated mechanisms. It also enhances the anticancer effects of platinum compounds and taxanes in non–small-cell lung cancer (NSCLC) cell lines. This phase II randomized, double-blinded, placebo-controlled study evaluated the efficacy of vorinostat in combination with carboplatin and paclitaxel in patients with advanced-stage NSCLC. Patients and Methods: Patients with previously untreated stage IIIB (ie, wet) or IV NSCLC were randomly assigned (2:1) to carboplatin (area under the curve, 6 mg/mL × min) and paclitaxel (200 mg/m 2 day 3) with either vorinostat (400 mg by mouth daily) or placebo. Vorinostat or placebo was given on days 1 through 14 of each 3-week cycle to a maximum of six cycles. The primary end point was comparison of the response rate. Results: Ninety-four patients initiated protocol therapy. Baseline patient characteristics were similar between the two arms. The median number of cycles was four for both treatment arms. The confirmed response rate was 34% with vorinostat versus 12.5% with placebo (P = .02). There was a trend toward improvement in median progression-free survival (6.0 months v 4.1 months; P = .48) and overall survival (13.0 months v 9.7 months; P = .17) in the vorinostat arm. Grade 4 platelet toxicity was more common with vorinostat (18% v 3%; P < .05). Nausea, emesis, fatigue, dehydration, and hyponatremia also were more frequent with vorinostat. Conclusion: Vorinostat enhances the efficacy of carboplatin and paclitaxel in patients with advanced NSCLC. HDAC inhibition is a promising therapeutic strategy for treatment of NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citationCOMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“The mechanisms by which HDAC inhibitors exert anticancer effects appear to be disease dependent and target dependent.(32) This study was prompted by promising activity noted in our phase I study with this combination.”
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 1×
“HDAC 6, located in the cytoplasm, deacetylates tubulin by binding to the microtubule motor complex.(33) Preclinical studies have documented synergistic tubulin acetylation and subsequent mitotic arrest when cells were exposed to paclitaxel in combination with tubacin, a specific inhibitor of HDAC 6.”
BackgroundCarboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Self-citationToutenburg, H. (1974) · Biometrische Zeitschrift · doi:10.1002/bimj.19740160814 · Cited by 1,538
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · cited 1×
“members of a novel class of anticancer agents that act by regulating chromatin structure and function.(6)”
BackgroundReck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,351
Dillman, R. O., Seagren, S. L., Propert, K. J., Guerra, J., Eaton, W. L., Perry, M. C., Carey, R. W., Frei, E. F., & Green, M. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231403 · Cited by 1,153
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141 · cited 1×
“treatment of patients with cutaneous T-cell lymphoma.(15) It is administered orally on either a continuous daily or intermittent schedule.”
BackgroundKelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Histone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 449
Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400 · cited 2×
“factor , and tubulin, also may contribute to the anticancer effects of HDAC inhibitors.(7-10) These”
BackgroundLuu, T. H., Morgan, R. J., Leong, L., Lim, D., McNamara, M., Portnow, J., Frankel, P., Smith, D. D., Doroshow, J. H., Gandara, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0122 · Cited by 237
Self-citationRamalingam, S. S., Parise, R. A., Ramananthan, R. K., Lagattuta, T. F., Musguire, L. A., Stoller, R. G., Potter, D. M., Argiris, A. E., Zwiebel, J. A., Egorin, M. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0162 · Cited by 193
Self-citationBali, P., Pranpat, M., Swaby, R., Fiskus, W., Yamaguchi, H., Balasis, M., Rocha, K., Wang, H.-G., Richon, V., & Bhalla, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0344 · Cited by 184
Maltepe, E., Krampitz, G. W., Okazaki, K. M., Red-Horse, K., Mak, W., Simon, M. C., & Fisher, S. J. (2005) · Development · doi:10.1242/dev.01923 · Cited by 169 · cited 1×
“factor , and tubulin, also may contribute to the anticancer effects of HDAC inhibitors.(7-10) These”
BackgroundBlumenschein, G. R., Kies, M. S., Papadimitrakopoulou, V. A., Lu, C., Kumar, A. J., Ricker, J. L., Chiao, J. H., Chen, C., & Frankel, S. R. (2008) · Investigational New Drugs · doi:10.1007/s10637-007-9075-2 · Cited by 167
Ramalingam, S. S., Belani, C. P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., & Gandara, D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318191520c · Cited by 159
Self-citationTraynor, A. M., Dubey, S., Eickhoff, J. C., Kolesar, J., Schell, K. A., Huie, M. S., Groteluschen, D. L., Marcotte, S. M., Hallahan, C. M., Weeks, H., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181952478 · Cited by 144
Self-citationBelani, C. P., Ramalingam, S., Perry, M. C., LaRocca, R. V., Rinaldi, D., Gable, P. S., & Tester, W. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1912 · Cited by 142
Self-citationSun, Y., Chin, Y. E., Weisiger, E., Malter, C., Tawara, I., Toubai, T., Gatza, E., Mascagni, P., Dinarello, C. A., & Reddy, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804388 · Cited by 126
Krug, L. M., Curley, T., Schwartz, L. B., Richardson, S., Marks, P. A., Chiao, J. H., & Kelly, W. K. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.n.003 · Cited by 120
Marcus, A. I., Zhou, J., O'Brate, A., Hamel, E., Wong, J., Nivens, M., El-Naggar, A., Yao, T.-P., Khuri, F. R., & Giannakakou, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3757 · Cited by 109
Vorinostat increases carboplatin and paclitaxel activity in non‐small cell lung cancer cells
Owonikoko, T. K., Ramalingam, S. S., Kanterewicz, B. I., Balius, T. E., Belani, C. P., & Hershberger, P. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24759 · Cited by 97
Self-citationNeužil, J., Swettenham, E., & Gellert, N. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.074 · Cited by 87
State-of-the-art chemotherapy for advanced non-small cell lung cancer
Ramalingam, S., & Belani, C. P. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.017 · Cited by 72
Self-citationHistone acetylation is involved in hsp70 gene transcription regulation in Drosophila melanogaster
Chen, T., Sun, H., Lü, J., Zhao, Y., Tao, D., Li, X., & Huang, B. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00564-7 · Cited by 50
Kanzaki, M., Kakinuma, H., Kumazawa, T., Inoue, T., Saito, M., Narita, S., Yuasa, T., Tsuchiya, N., & Habuchi, T. (2007) · Oncology Reports · doi:10.3892/or.17.4.761 · Cited by 30
Trédaniel, J., Descourt, R., Moro‐Sibilot, D., Misset, J. L., Gachard, E., Garcia-Vargas, J. E., Roben, E., & Zalcman, G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8049 · Cited by 14
Cited by
Epigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
“SAHA improved effect of carboplatin and paclitaxel in NSCLC [178] and reversed resistance to tamoxifen in estrogen receptor positive breast cancer [179].”
BackgroundInfluentialLung cancer: Biology and treatment options
Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y.-W., & Buchanan, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,014
Epigenetic modifications as therapeutic targets
Kelly, T. K., De Carvalho, D. D., & Jones, P. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1678 · Cited by 793
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Metadata
- Authors
- Ramalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., & Belani, C. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-01
- Volume
- 28
- Issue
- 1
- Pages
- 56-62
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2132037667
- Cited by
- 273
- References
- 39
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.